BridgeBio Pharma (BBIO) EBT Margin (2019 - 2026)
BridgeBio Pharma (BBIO) posted EBT Margin of 61.71% for Q1 2026, up 51.15% sequentially from 126.32% in Q4 2025, and up 4312.0% YoY from 1.4% in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) EBT Margin (2019 - 2026) Analysis & Trends
BridgeBio Pharma has reported EBT Margin for 8 years, with the latest figure at 61.71% in Q1 2026.
- Quarterly EBT Margin rose 4312.0% year-over-year to 61.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 117.75% (up 37535.0% YoY) and the FY2025 annual result came in at 145.89%, up 9844.0% from the prior year.
- EBT Margin rose to 61.71% in Q1 2026 per BBIO's latest filing, from 126.32% in the prior quarter.
- Over five years, EBT Margin peaked at 16.58% in Q1 2024 and troughed at 43350.3% in Q3 2022.
- A 5-year average of 6557.17% and a median of 4258.25% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 3590303 bps in 2022, then surged 3909205 bps in 2023.
- Over 5 years, EBT Margin stood at 7760.96% in 2022, then sank by 49 bps to 11593.18% in 2023, then soared by 61 bps to 4526.28% in 2024, then surged by 97 bps to 126.32% in 2025, then jumped by 51 bps to 61.71% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 61.71%, 126.32%, and 154.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -63.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.97% |
| Mar 31, 2026 | -61.14% |
| Dec 31, 2025 | -126.32% |
| Sep 30, 2025 | -154.50% |
| Jun 30, 2025 | -164.30% |
| Mar 31, 2025 | -105.03% |
| Dec 31, 2024 | -4,526.28% |
| Sep 30, 2024 | -6,012.23% |
| Jun 30, 2024 | -3,484.50% |
| Mar 31, 2024 | -10.97% |
| Dec 31, 2023 | -11,008.94% |
| Sep 30, 2023 | -4,258.25% |
| Jun 30, 2023 | -10,153.44% |
| Mar 31, 2023 | -7,993.87% |
| Dec 31, 2022 | -7,760.96% |
| Sep 30, 2022 | -43,350.30% |
| Jun 30, 2022 | -136.28% |
| Mar 31, 2022 | -11,468.30% |
| Dec 31, 2021 | -1,805.66% |
| Sep 30, 2021 | -6,840.10% |